Novel Drug Delivery Systems Market by Route of Administration, Mode, End-User

Description

List of Tables

[190 Pages Report] The Novel Drug Delivery Systems Market size was estimated at USD 13.83 billion in 2023 and expected to reach USD 15.00 billion in 2024, at a CAGR 9.17% to reach USD 25.57 billion by 2030.

Novel drug delivery systems (NDDS) refer to the advanced methods and technologies used in pharmaceuticals to formulate medicines that can be delivered to the body in non-traditional ways. The market for novel drug delivery systems encompasses diverse technologies and methodologies designed to transport pharmaceutical compounds to specific parts of the body to enhance efficacy, control drug release, and improve patient compliance. The prevalence of chronic diseases, a significant rise in the geriatric population, and advancements in controlled drug release technologies are influencing the growth of the novel drug delivery systems market. Government approvals for novel drug delivery systems are accelerating the market's growth. Existing limitations associated with novel drug delivery systems, complications, and expertise required in delivering therapeutics and drugs may limit scalability and widespread usage. Ongoing advancements in developing novel drug delivery systems and the rising adoption of self-injectable devices are expected to provide growth opportunities in the market.

KEY MARKET STATISTICS
Base Year [2023]	USD 13.83 billion
Estimated Year [2024]	USD 15.00 billion
Forecast Year [2030]	USD 25.57 billion
CAGR (%)	9.17%

Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management

Injectable drug delivery systems are designed for direct delivery of drugs into the body's circulation. These systems are typically preferred for rapid onset of action, for drugs with poor oral bioavailability, and for targeted drug delivery. Oral drug delivery systems are the most common route, favored for ease of administration, patient compliance, and cost-effectiveness. Innovations in this category aim to improve solubility and absorption, controlled release, and precise targeting to the site of action to minimize side effects. Pulmonary drug delivery systems are employed for localized treatment of respiratory diseases and systemic delivery of certain drugs. They offer non-invasive rapid systemic absorption, highlighting nebulizers, metered-dose inhalers, and dry powder inhalers. Transdermal drug delivery systems administer drugs through the skin for systemic effects. Preferred when oral routes are unsuitable or to avoid first-pass metabolism, advancements include patches, gels, and microneedle technologies. A comparative analysis reveals that injectables excel in terms of drug bioavailability and targeted delivery but lag in patient convenience. Oral systems offer convenience and cost efficiency, yet vary in bioavailability. Pulmonary methods provide fast absorption and are relatively easy to use, while transdermal systems offer sustained delivery and good patient compliance, though with potential limits on the types of drugs that can be effectively delivered.

End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base

Hospitals represent the largest segment of novel drug delivery systems. Their primary concern is delivering patient-centered care with improved outcomes. Hospitals seek drug delivery systems that are safe and effective with a high degree of control over drug release. Research centers prioritize innovation and cutting-edge technologies in drug delivery systems. They focus on advanced drug delivery mechanisms that allow precise targeting and release of drugs. The specialty clinics segment seeks specialized and targeted drug delivery systems that support their focus on particular medical disciplines or diseases. Specialty clinics prefer disease-specific delivery systems that optimize therapeutic outcomes. While all segments value innovation, research centers emphasize cutting-edge delivery methods, followed by specialty clinics requiring disease-specific innovations. Hospitals have a strong need for systems that integrate seamlessly with existing health information technologies for better monitoring and compliance.

Regional Insights

The novel drug delivery systems (NDDS) market in the Americas is driven by robust technological advancements and significant investments in research and development, with a strong focus on personalized medicine. The presence of key pharmaceutical companies and a well-established healthcare infrastructure contribute to the pioneering position of this region. The regulatory framework facilitated by the FDA in the United States sets a conducive environment for introducing and adopting innovative drug delivery solutions. South America's market for NDDS is emerging with growing awareness and increasing healthcare expenditure. Europe has the highest adoption of NDDS, backed by strong governmental support and high-quality healthcare systems. In contrast, the Middle East and Africa are also adapting to the advancements owing to increasing strategic partnerships and investments in healthcare sectors. The Asia-Pacific region is witnessing significant growth in the NDDS market attributed to growing economies and increasing healthcare investments. Due to their technological capabilities and substantial healthcare spending, China and Japan are major countries. Additionally, the growing pharmaceutical sectors in India and Southeast Asia are contributing significantly to the expansion of the NDDS market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Novel Drug Delivery Systems Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Novel Drug Delivery Systems Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Novel Drug Delivery Systems Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AstraZeneca Plc, Bayer AG, Boston Scientific Corporation, Bristol Myers Squibb Company, Cospheric LLC, Enable Injections, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Insulet Corporation, Johnson & Johnson Services, Inc., Lonza Group Ltd., Merck KGaA, Merit Medical Systems, Inc., Mo-Sci Corporation, Novartis AG, Pacira BioSciences, Inc., Pfizer Inc., Polysciences Inc., Sanofi S.A., Societal CDMO, Spectrum Pharmaceuticals, Inc., Terumo Medical Corporation, Thermo Fisher Scientific Inc., and West Pharmaceutical Services, Inc..

Market Segmentation & Coverage

This research report categorizes the Novel Drug Delivery Systems Market to forecast the revenues and analyze trends in each of the following sub-markets:

Route of Administration
- Injectable Drug Delivery Systems
- Oral Drug Delivery Systems
- Pulmonary Drug Delivery Systems
- Transdermal Drug Delivery Systems

Mode
- Controlled Drug Delivery Systems
- Modulated Drug Delivery Systems
- Targeted Drug Delivery Systems

End-User
- Hospital
- Research Centers
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Novel Drug Delivery Systems Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Novel Drug Delivery Systems Market?

3. What are the technology trends and regulatory frameworks in the Novel Drug Delivery Systems Market?

4. What is the market share of the leading vendors in the Novel Drug Delivery Systems Market?

5. Which modes and strategic moves are suitable for entering the Novel Drug Delivery Systems Market?

Product Code: MRR-02026C4CB9B9

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of Chronic Diseases and Significant Rise in Geriatric Population
  - 5.1.1.2. Advancements in Controlled Drug Release Technologies
  - 5.1.1.3. Government Approvals for Novel Drug Delivery Systems
- 5.1.2. Restraints
  - 5.1.2.1. Existing Limitations Associated with Novel Drug Delivery System
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing Advancements for Development of Novel Drug Delivery Systems
  - 5.1.3.2. Rising Adoption of Self-Injectable Devices
- 5.1.4. Challenges
  - 5.1.4.1. Complications and Expertise Required in Delivering Therapeutics and Drugs
5.2. Market Segmentation Analysis
- 5.2.1. Route of Administration: Rising adoption of injectable drug delivery systems for chronic disease management
- 5.2.2. End-User: Increasing use of novel drug delivery systems in the hospital due to budget constraints and the necessity to cater to a larger patient base
5.3. Market Trend Analysis
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework Analysis
5.9. Client Customization

6. Novel Drug Delivery Systems Market, by Route of Administration

6.1. Introduction
6.2. Injectable Drug Delivery Systems
6.3. Oral Drug Delivery Systems
6.4. Pulmonary Drug Delivery Systems
6.5. Transdermal Drug Delivery Systems

7. Novel Drug Delivery Systems Market, by Mode

7.1. Introduction
7.2. Controlled Drug Delivery Systems
7.3. Modulated Drug Delivery Systems
7.4. Targeted Drug Delivery Systems

8. Novel Drug Delivery Systems Market, by End-User

8.1. Introduction
8.2. Hospital
8.3. Research Centers
8.4. Specialty Clinics

9. Americas Novel Drug Delivery Systems Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Novel Drug Delivery Systems Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Novel Drug Delivery Systems Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Novel drug delivery one-stop shop
- 12.3.2. Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
- 12.3.3. Kindeva Drug Delivery acquires Summit Biosciences

13. Competitive Portfolio

13.1. Key Company Profiles
13.2. Key Product Portfolio